PYCR1

Across TCGA pan-cancer cohorts, PYCR1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PYCR1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PYCR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PYCR1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where PYCR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.462	0.850	.003	45	view →
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	36	view →
LSCC	DFS	Median	All	0.397	0.918	.001	6	view →
GBM	OS	Median	All	0.262	0.501	.007	5	view →
LUAD	DFS	Quartile	III,IV	0.867	0.264	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PYCR1–PDAC (DFS)

Open the PDAC breakdown →